Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02092922 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT02092922 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 154 participants.
The verdict
NCT02092922, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
The AfFIRM Study is a Phase 2 study during which patients with advanced multiple myeloma will receive single-agent investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of filanesib in treating myeloma. Approximately 160 patients from North America and Europe will be enrolled in this study. Eligible patients will have received at least two prior lines of therapy; have received prior bortezomib and lenalidomide; and have disease refractory to carfilzomib and/or pomalidomide.
Interventions
- DRUG Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
- DRUG Filanesib, KSP (Eg5) inhibitor; intravenous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02092922
The ClinicalTrials.gov registry entry for NCT02092922 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous is the first listed.
NCT02092922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02092922 about?
NCT02092922 is a clinical study titled "A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)". The AfFIRM Study is a Phase 2 study during which patients with advanced multiple myeloma will receive single-agent investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of filanesib in treating myeloma. Approximately 160 patients from North America...
What is the current status of trial NCT02092922?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2014-05. Estimated completion is 2017-09-05.
What interventions are being tested in trial NCT02092922?
The interventions under investigation include: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous (DRUG), Filanesib, KSP (Eg5) inhibitor; intravenous (DRUG).
Who is sponsoring clinical trial NCT02092922?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.